SLC34A1 and nephrolithiasis: Our GWAS meta-analysis identified an intergenic variant, rs10051765, approximately 6 Kbp upstream of SLC34A1, that is associated with an increased risk of kidney stones, increased albumin-adjusted serum calcium, and decreased serum phosphate concentrations, which drives effects of decreasing serum phosphate concentrations on risk of kidney stone disease.